<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083161</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000363799</org_study_id>
    <secondary_id>GLO-03-06-06</secondary_id>
    <nct_id>NCT00083161</nct_id>
  </id_info>
  <brief_title>Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
  <official_title>Pilot Study of a Combination of Standard Etoposide/Cisplatin and Metronomic Cyclophosphamide in Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gundersen Lutheran Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gundersen Lutheran Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and cyclophosphamide,&#xD;
      work in different ways to stop tumor cells from dividing so they stop growing or die.&#xD;
      Combining more than one chemotherapy drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving cisplatin, etoposide, and&#xD;
      cyclophosphamide together works in treating patients with extensive-stage small cell lung&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of cisplatin, etoposide, and cyclophosphamide in patients with&#xD;
           extensive stage small cell lung cancer.&#xD;
&#xD;
        -  Determine the effect of this regimen on circulating endothelial cells in the peripheral&#xD;
           blood of these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine progression-free survival, tumor response rate, and overall survival in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Induction therapy: Patients receive cisplatin IV over 30 minutes-2 hours on day 1,&#xD;
           etoposide IV over 1-2 hours on days 1-3 OR etoposide IV on day 1 and orally twice daily&#xD;
           on days 2-3, and oral cyclophosphamide twice daily on days 8-19. Treatment repeats every&#xD;
           21 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Maintenance therapy: Patients receive oral cyclophosphamide twice daily in the absence&#xD;
           of disease progression.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>From time of registration to 30 days post treatment of last cycle.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of metronomic chemotherapy on circulating endothelial cells</measure>
    <time_frame>Baseline to progression</time_frame>
    <description>Collected cycle 1/day 1 of chemotherapy, Cycle 1/day 8, cycle 1/day 22, and then day 85 and 141, and at disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Registration to time of progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>From Registration to time of disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From registration to time patient expires</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Oral cyclophosphamide plus standard cisplatin with etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etoposide 120 mg/m2 IV Days 1-3 or Etoposide 120 mg/ m2 IV Day1 followed by Etoposide 120 mg/ m2 PO BID Days 2-3&#xD;
Cisplatin 60 mg/m2 IV Day 1 Every 21 days x 4 cycles&#xD;
Cyclophosphamide 25 mg PO BID Days 8-19 of each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>60 mg/m2 IV day 1, every 21 days for 4 cycles.</description>
    <arm_group_label>Oral cyclophosphamide plus standard cisplatin with etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression</description>
    <arm_group_label>Oral cyclophosphamide plus standard cisplatin with etoposide</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3</description>
    <arm_group_label>Oral cyclophosphamide plus standard cisplatin with etoposide</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed small cell lung cancer&#xD;
&#xD;
               -  Extensive stage disease (i.e., disease beyond the hemithorax and cannot be&#xD;
                  encompassed safely by a tolerable radiation field)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Concurrent CNS metastases allowed provided patient remains asymptomatic&#xD;
&#xD;
               -  Radiotherapy or surgery for uncontrolled symptoms allowed before study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past year except adequately treated basal cell or&#xD;
             squamous cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids for brain metastases allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior radiotherapy to any symptomatic site allowed provided the target site(s) was not&#xD;
             previously irradiated&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald S. Go, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gundersen Lutheran Center for Cancer and Blood</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gundersen Lutheran Center for Cancer and Blood</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2004</study_first_posted>
  <last_update_submitted>September 1, 2012</last_update_submitted>
  <last_update_submitted_qc>September 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gundersen Lutheran Health System</investigator_affiliation>
    <investigator_full_name>Ronald Go</investigator_full_name>
    <investigator_title>Hematologist</investigator_title>
  </responsible_party>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

